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Intravenous administration to volunteers of an emulsion of medium-chain lipids, but not of an emulsion of
pure long-chain lipids or a placebo, increased the growth of Candida albicans in serum and modulated
Candida-induced cytokine production by mononuclear cells in a way suggesting that medium-chain, but not
long-chain, triglycerides increase the risk for infections by Candida.
The provision of total parenteral nutrition (TPN) is an in-
dispensable strategy to improve the nutritional status of criti-
cally ill patients. However, altered immune responses by the
TPN lipid component may contribute to the increased rate of
infectious complications for these patients (43). It remains
unclear whether structurally different lipid emulsions contain-
ing either pure long-chain triglycerides (LCT) or mixed long-
and medium-chain triglycerides (LCT-MCT) exert distinct im-
mune-modulating effects (1, 3, 4, 7, 8, 10, 12–15, 18, 25, 27, 28,
32, 33, 35–37, 40, 42, 43, 44). Recently, we found that LCT-
MCT, unlike LCT, increase in vitro oxygen radical production
and adhesion of neutrophils but decrease cellular motility and
killing of Candida albicans (20, 45–48). This observation is
important because clinical studies indicate that 5% of all pa-
tients receiving TPN develop candidemia, with significant mor-
tality and morbidity (38).
In the present study, we exposed LCT and LCT-MCT to the
metabolisms and immune systems of healthy volunteers. We
investigated the effects of lipids on two pathogenetic aspects of
Candida infections: yeast growth and the balance of proinflam-
matory (gamma interferon [-IFN], tumor necrosis factor al-
pha [TNF-], interleukin-1 [IL-1], and IL-6) and anti-in-
flammatory (IL-10) cytokines (2, 19, 29, 30, 34, 41).
Emulsions containing LCT, LCT-MCT, or saline were ad-
ministered during 4 h to eight volunteers in a study with a
crossover design and a 1-week washout period. Blood samples
were taken before and after 4 h of lipid or placebo adminis-
tration and analyzed as described below. In order to stabilize
plasma triglyceride concentrations at a clinically relevant con-
centration of 3 to 5 mmol/liter, emulsions (overall, ca. 220 ml)
were infused according to a triglyceride-clamp schedule (16,
17). For emulsion characteristics, see Table 1.
Leukocytes were isolated from 20 ml of blood anticoagu-
lated with lithium-heparin (6, 21, 45). Peripheral blood mono-
nuclear cells (PBMC) were removed and suspended in me-
dium (RPMI 1640 DM; Flow Laboratories, Irvine, United
Kingdom). Heat-killed C. albicans (strain UC820; final con-
centration, 107 CFU/ml) was used for ex vivo PBMC stimula-
tion in the cytokine assays. After PBMC isolation, cell numbers
were adjusted (5  106/ml) and cell suspension samples were
incubated with Candida (24 h, 37°C). After incubation, the
supernatants were frozen (20°C) until assayed. IL-1 and
TNF- (both in nanograms per milliliter) in supernatants were
measured by radioimmunoassays as described previously (23).
Detection limits of the assay were 20 pg/ml for TNF- and 40
pg/ml for IL-1. Interassay variation was less than 15%, and
intra-assay variation was less than 10%. IL-6, IL-8, IL-10, and
IFN- concentrations were determined in duplicate with com-
mercially available enzyme-linked immunosorbent assay kits
(Pelikine Compact human enzyme-linked immunosorbent as-
say; CLB, Amsterdam, The Netherlands).
After inoculation and overnight culturing, C. albicans was
suspended at 106 CFU/ml. The Candida suspension was incu-
bated (24 h, 37°C) with serum samples and Sabouraud me-
dium. After incubation, samples were plated onto Sabouraud
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TABLE 1. Characteristics of lipid emulsions according
to manufacturers
Component or characteristic LCT LCT-MCT
Fractionated soybean oil (g/liter) 200 100
MCT (g/liter) 0 100
Fatty acids (% [wt/wt] of total)
Caproic acid (C6:0) 0.5
Caprylic acid (C8:0) 28.5
Capric acid (C10:0) 20
Lauric acid (C12:0) 1
Palmitic acid (C16:0) 9 6.5
Stearic acid (C18:0) 5 2
Oleic acid (C18:1) 25 11
Linoleic cid (C18:2) 55 26
Linolenic acid (C18:3) 8 4
Arachidonic acid (C20:4) 1 0.5
Mean molecular weight of triglycerides 865 634
Fractionated egg phospholipids (g/liter) 12 12













agar plates and incubated (29°C) for 8 and 24 h. The colonies
were counted (numbers of CFU per milliliter), and growth
rates were expressed as ratios of numbers of CFU in samples
after lipid administration to those before lipid administration.
Results are expressed as medians (with 25th and 75th per-
centiles). The statistical significance of treatment effects was
determined by analysis of variance with Bonferroni correction
for multiple comparisons and by Tukey’s posttest.
Infusion of LCT and LCT-MCT equally increased triglycer-
ide concentrations (Table 2). However, ex vivo cytokine pro-
duction by PBMC was distinctly influenced by lipid treatment
(Table 3). Candida-induced production of TNF-, IL-1, and
IL-10 increased after LCT-MCT exposure. Compared with the
placebo, LCT showed no effect, although this might be due to
the sample size. Candida-induced IFN- production tended to
decrease, but values did not reach statistical significance. In-
fusion of LCT or placebo, with this limited sample size, did not
influence the production of any cytokine. With LCT-MCT, we
observed a significantly increased rate of growth of Candida
after 8 and 24 h compared with rates with the placebo and LCT
(Fig. 1).
Infections by C. albicans pose a threat to the use of NADP
(9, 38). Outcomes probably depend on yeast growth rates as
well as counteractive responses of the innate and adaptive
immune systems (30, 31). It appears that the balance of pro-
and anti-inflammatory cytokines is altered by LCT-MCT in a
way that is known to deactivate innate immunity (30, 31). Also,
our results indicate that LCT-MCT, but not LCT, favors the
development of Candida infections by enhancing yeast growth
rates. Microscopic evaluation (data not shown) revealed the
formation of pseudohyphae after lipid administration, indicat-
ing that growth rates are underestimated even in our experi-
mental setting. Importantly, inhibitory effects of serum on
yeast growth due to iron deprivation were ruled out, as addi-
tion of FeCl3 (10 mol/liter) to serum did not affect test results
(data not shown).
Our ex vivo findings support in vitro work where LCT-MCT,
but not LCT, impaired neutrophil killing of Candida (48).
Previous in vitro studies with LCT showed that Candida grows
better in a lipid-rich environment (5, 11, 24, 36). We did not
find a growth-enhancing effect on Candida for parenteral LCT,
suggesting that with its metabolic breakdown, the effects of
LCT on candidal growth disappear, in contrast with what oc-
curs with MCT.
The relative importance of the findings of increased levels of
TNF-, IL-1, and (to a lesser extent) IL-8 production with
MCT, which could be considered protective, remains unclear
and probably can be evaluated only in a clinical study.
The altered balance of Candida-induced cytokine produc-
tion by PBMC, with increased production of IL-10 (by Th2
lymphocytes) and unchanged or decreased production of
IFN- (by Th1 lymphocytes), results in a decreased IFN-/
IL-10 ratio. Such an imbalance in Th1 and Th2 responses is
considered a major risk factor for the development of fungal
infections (30, 34, 41). On the other hand, it is also possible
that the IL-10 measured in our experiments was produced by
monocytes.
IFN- activates phagocytic cells to kill Candida, whereas
IL-10 has been shown to inhibit proinflammatory cytokine
production and to aggravate the course of disseminated can-
didiasis (22, 26, 39). The influence of LCT-MCT on the pro-
duction of IFN- (decreased production) and monokines (in-
creased production), in combination with the lack of effects of
LCT, suggests that MCT have differential effects on T cells and
TABLE 2. Effects of lipid administration on triglyceride concentrations
Infusion
Triglyceride concn (25th, 75th percentiles)a
Before infusion After infusion After  before infusion
Placebo 1.48 (1.04, 1.94) 1.06 (0.70, 1.74) 0.11 (0.50, 0.10)
LCT 0.97 (0.79, 1.46) 3.15 (2.64, 3.89)b 1.67 (0.96, 2.36)c
LCT-MCT 1.28 (0.80, 1.44) 3.54 (2.24, 4.47)b 2.43 (1.41, 5.04)c
a Triglyceride concentrations (in millimoles per liter) in subjects before and after a 4-h infusion of lipids or the placebo.
b Significant change versus values for the preinfusion concentration.
c Significant change versus values for the preinfusion concentration and the concentration with the placebo.
TABLE 3. Effects of lipid administration on cytokine production by PBMC
Stimulus Cytokine
Concn (mmol/liter) (25th, 75th percentiles) witha:
ANOVAb result
Placebo LCT LCT-MCT
Candida IFN- 1.01 (0.41, 1.66) 1.00 (0.76, 1.24) 0.38 (0.12, 0.71) 0.11
IL-10 0.82 (0.58, 0.96) 0.76 (0.61, 0.95) 1.87 (1.08, 2.90)c,d 0.03
TNF- 0.69 (0.38, 0.96) 1.24 (0.96, 1.53) 2.01 (1.49, 5.34)c 0.04
IL-1 0.64 (0.44, 0.78) 1.07 (0.78, 1.21) 1.75 (1.42, 2.58)c,d 0.01
IL-6 0.74 (0.54, 1.36) 0.81 (0.60, 1.28) 1.86 (0.94, 3.74) 0.16
IL-8 0.83 (0.71, 0.97) 1.09 (0.93, 1.24) 1.35 (0.87, 1.82) 0.38
a Effects of lipids or a placebo on the ratio of cytokine production by PBMC before the infusion to that after the infusion.
b ANOVA, analysis of variance.
c , significant effect versus the effect with the placebo.
d , significant effect of LCT-MCT versus the effect with LCT.











monocytes. LCT exerted no effects on cytokine production
compared with the placebo, making it improbable that com-
ponents other than the lipids, e.g., an emulsifier and antioxi-
dants, are responsible for the emulsion effects. Finally, it has to
be kept in mind that definite proof for the effects of lipids on
the susceptibility to fungal infections of humans can be ob-
tained only in large-scale clinical studies.
In conclusion, the results of our study suggest that paren-
teral MCT, contrary to pure LCT, increase susceptibility to
infections with C. albicans by increasing candidal growth rates
and by having a detrimental effect on antifungal immune re-
sponses.
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